Dolutegravir 50mg / Lamivudine 300mg tablets
NHS hospitals in England used £173,732,663 of indicative cost of Dolutegravir 50mg / Lamivudine 300mg tablets in the 12 months to April 2026, about 0.7% of all hospital medicines spend. That is up 31.8% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Dolutegravir 50mg / Lamivudine 300mg tablets: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Dolutegravir 50mg / Lamivudine 300mg tablets most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Chelsea & Westminster Hospital Nhs Ft | £21,535,584 |
| Royal Free London Nhs Foundation Trust | £11,759,172 |
| Manchester University Nhs Ft | £7,742,838 |
| University College London Foundation Tr | £7,250,184 |
| Ctrl & N W London Nhs Foundation Trust | £5,636,355 |
| University Hpls Of Leicester Nhs Trust | £5,459,010 |
| Aintree University Hospital Nhs Ft | £5,408,280 |
| North Bristol Nhs Trust | £5,333,118 |
| Univ Hpl B/Ham Nhs Foundation Trust | £5,170,563 |
| Barts Health Nhs Trust | £4,883,230 |
The primary-care picture
Dolutegravir is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Dolutegravir medicine page.